Mitochondrial COX4I2 drives pericyte-dependent inflammation and emphysema

View at publisher
Authors: Claudia F. Garcia Castro, Vidya Srokshna Balasubramanian Lakshmi, Stefan Hadžić, Claudio Nardiello, Rolf David Glaser, Maik Hüttemann, Lawrence I. Grossman, Baktybek K. Kojonazarov, Muchen Li, Sandipan Jash, Janine Koepke, Marija Gredic
+24 more C Y Wu, Luca Giordano, Matthias Hecker, Christos Samakovlis, Edma Loku, Anis Cilic, Julian Better, Ulrich Matt, Brigitte Mueller, Knut Stieger, Lyubomyr M. Lytvynchuk, Learta Pervizaj-Oruqaj, Andreas Günther, Jochen Wilhelm, Susanne Herold, Slaven Crnković, Grażyna Kwapiszewska, Michael P. Murphy, Friedrich Grimminger, Marek Bartkuhn, Werner Seeger, Norbert Weißmann, Oleg Pak, Natascha Sommer
Cited by: 0
References: 69

Abstract

Abstract Chronic obstructive pulmonary disease (COPD) is characterized by neutrophilic inflammation, emphysema, and mild pulmonary hypertension (PH). Oxidative/nitrosative stress are key drivers, but specific mitochondrial mechanisms remain unclear. We show increased expression of the regulatory mitochondrial cytochrome c oxidase subunit 4 isoform 2 (COX4I2) in an early murine model and human COPD. After 8 months of cigarette smoke exposure, Cox4i2 −/− mice were completely protected from emphysema but not from PH, associated with reduced nitrosative stress, inflammation, and apoptosis. Using a novel Cox4i2 reporter mouse and in situ hybridization of human lungs, COX4I2 was detected in precapillary ACTA2 + cells and capillary pericytes. COX4I2 promotes mitochondrial reactive oxygen species (mtROS) production in these cells, thereby enhancing neutrophil migration and alveolar type II cell apoptosis, and modulates angiogenesis. In contrast to Cox4i2 −/− , mitochondria-targeted antioxidant MitoQ reversed emphysema and PH, suggesting pericyte-specific regulation of COPD pathologies and mtROS inhibition as a therapeutic approach in COPD. Graphical abstract

Fields of Study & Subjects

Chronic Obstructive Pulmonary Disease (COPD) Research Mitochondrial Function and Pathology Pulmonary Hypertension Research and Treatments

Publication details

Journal / source
bioRxiv (Cold Spring Harbor Laboratory)
Publication date
9 February 2026
Language
EN
Document type
Preprint